Acura Pharmaceuticals Inc (ACUR):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C10003)
◆英語タイトル:Acura Pharmaceuticals Inc (ACUR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10003
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:35
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Acura Pharmaceuticals Inc (Acura) is a specialty pharmaceutical company that researches, develops, and commercializes tamper-resistant products to prevent the abuse and misuse of medication. The company’s proprietary technologies, Aversion, Limitx and Impede, are used to prevent product tampering associated with opioid abuse. Its Impede technology helps minimize the extraction and conversion of pseudoephedrine into methamphetamine. Limitx reduces the level of opioid release when several tablets are swallowed. Aversion irritates the nasal passages upon snorting the product. Its product portfolio includes Oxaydo, an opioid analgesic; Nexafed and Nexafed Sinus Pressure plus that contain pseudoephedrine. The company markets its products in the US and Canada. Acura is headquartered in Palatine, Illinois, the US.

Acura Pharmaceuticals Inc (ACUR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Acura Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Licensing Agreements 12
MainPointe Pharma Enters into Licensing Agreement with Acura Pharma 12
KemPharm Enters into Licensing Agreement with Acura Pharma 14
Egalet Enters into Licensing Agreement with Acura Pharma 15
Equity Offering 16
Acura Pharma Raises USD4 Million in Private Placement of Units 16
Acura Pharmaceuticals Files Registration Statement for Public Offering of Shares 17
Acura Pharma Raises USD7.6 Million in Private Placement of Shares 18
Acura Pharma Completes Second Tranche Of Public Offering Of Shares For US$3.4 Million 20
Acquisition 21
Acura Pharma Plans to Sell Itself 21
Acura Pharmaceuticals Inc – Key Competitors 22
Acura Pharmaceuticals Inc – Key Employees 23
Acura Pharmaceuticals Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Aug 14, 2018: Acura Pharmaceuticals announces second quarter 2018 financial results 25
Jun 29, 2018: Acura Pharmaceuticals Reports First Quarter 2018 Financial Results 26
Jun 07, 2018: Acura Pharmaceuticals Announces Fourth Quarter 2017 and Full Year 2017 Financial Results 27
Nov 13, 2017: Acura Pharmaceuticals Announces Third Quarter 2017 Financial Results 28
Aug 14, 2017: Acura Pharmaceuticals Announces Second Quarter 2017 Financial Results 29
May 12, 2017: Acura Pharmaceuticals Announces First Quarter 2017 Financial Results 30
Mar 31, 2017: Acura Pharmaceuticals Announces Fourth Quarter 2016 and Full Year 2016 Financial Results 31
Product News 32
09/11/2017: Acura Pharmaceuticals Presenting New LIMITx Clinical Data at the 19th Annual Rodman & Renshaw Conference 32
06/28/2017: Acura Pharmaceuticals Advances LTX-04 and its LIMITx Technology 33
Clinical Trials 34
May 18, 2017: Acura Pharmaceutical Initiates Second Clinical Study on LTX-04 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acura Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Acura Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MainPointe Pharma Enters into Licensing Agreement with Acura Pharma 12
KemPharm Enters into Licensing Agreement with Acura Pharma 14
Egalet Enters into Licensing Agreement with Acura Pharma 15
Acura Pharma Raises USD4 Million in Private Placement of Units 16
Acura Pharmaceuticals Files Registration Statement for Public Offering of Shares 17
Acura Pharma Raises USD7.6 Million in Private Placement of Shares 18
Acura Pharma Completes Second Tranche Of Public Offering Of Shares For US$3.4 Million 20
Acura Pharma Plans to Sell Itself 21
Acura Pharmaceuticals Inc, Key Competitors 22
Acura Pharmaceuticals Inc, Key Employees 23
Acura Pharmaceuticals Inc, Subsidiaries 24

List of Figures
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Acura Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Acura Pharmaceuticals Inc (ACUR):製薬・医療:M&Aディール及び事業提携情報(Acura Pharmaceuticals Inc (ACUR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆